argenx is a global immunology company focused on the discovery and development of antibody-based therapies for severe autoimmune and inflammatory diseases. Leveraging its proprietary SIMPLE Antibody platform, the company engineers next-generation antibodies designed to engage immune system targets with high specificity. Headquartered in the Netherlands with research and commercial operations in the United States, argenx seeks to translate its deep scientific expertise into novel treatments that address critical, unmet medical needs.
The company’s lead product candidate, efgartigimod (Vyvgart), is a first-in-class neonatal Fc receptor (FcRn) blocker that selectively reduces pathogenic IgG autoantibodies. Efgartigimod is approved in multiple markets for the treatment of generalized myasthenia gravis and is under regulatory review or in late-stage studies for immune thrombocytopenia and other autoimmune disorders. Argenx’s broader pipeline includes bispecific and multispecific antibodies targeting oncology and neuromuscular indications, as well as programs in preclinical development aimed at expanding its immunomodulatory portfolio.
Founded in 2008 by Dr. Tim Van Hauwermeiren and Dr. Roel Opdenbosch, argenx has grown through strategic collaborations with biopharmaceutical partners and academic institutions. The company maintains research sites in Europe and North America, supported by manufacturing capabilities and commercial infrastructure poised to bring therapies to patients worldwide. Argenx’s approach combines cutting-edge antibody engineering with a patient-centric development model to accelerate clinical progress.
Under the guidance of a seasoned leadership team with deep backgrounds in immunology, drug development, and global commercialization, argenx continues to advance its mission of delivering life-changing therapies. The company’s board and executive officers bring decades of industry experience, positioning argenx to navigate regulatory pathways and scale its operations as it transitions from a clinical-stage organization to a fully integrated biopharmaceutical company.
AI Generated. May Contain Errors.